Navigation Links
Patent for Making Combination Chemotherapy Work Better
Date:3/24/2009

SAN JOSE, Calif., March 24 /PRNewswire/ -- Patent 7,507,704 issued on 03/24/09 to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose, California discloses an improved method of treating lung, brain, pancreatic, breast and colon cancers that are driven by a mutation known as HER1 overexpression (also called EGFR or c-ErbB-1). The patent presents a case for why today's concurrent HER1 blocker / S-Phase cytotoxic protocols achieve only a fraction of the potential inherent in the combination of the underlying drugs. Novel synergistic protocols are provided.

All proliferating cells progress through 4 distinct phases, in sequence, G1, S, G2, and M. "S-Phase cytotoxics, such as Pfizer's irinotecan or Eli Lilly's gemcitabine, are capable of killing virtually all cells that are in the S-Phase, however, less than one third of cancer cells are typically in the S-Phase during chemotherapy," explains Mark Zamoyski, the inventor. "Mechanistically, HER1 blockers, such as Genentech's erlotinib, AstraZeneca's gefitinib, ImClone's cetuximab and Amgen's panitumumab arrest and aggregate HER1 overexpressing cancer cells in the G1-Phase. This results in S-Phase depletion, greatly reducing the number of cancer cells killed by the S-Phase cytotoxic." The patent provides a crucial modification to the protocols by adding existing drugs to provide S-Phase enrichment at the appropriate time, while using the HER1 blocker to inhibit tumor regrowth between administrations of S-Phase cytotoxic.

Patent 7,507,704 is the third in a series of patents awarded to Mr. Zamoyski for cancer specific S-Phase enrichment relative to administrations of S-Phase cytotoxic chemotherapy. "With less than one third of cancer cells in the S-Phase, today's cytotoxic protocols only extend life expectancy by a few months. Doubling the number of cancer cells in the S-Phase would provide a way of indefinitely keeping most cancers in check. Tripling the number, while simultaneously preventing tumor regrowth between administrations of S-Phase cytotoxic, is required under established principles of chemotherapy for curative outcome. Drugs capable of doing both already exist for many cancers, providing the potential for an immediate advance in cancer treatment under our protocols," according to Mr. Zamoyski. Richard Lepidi, NexGen's business advisor, concludes "The IP has now reached a critical mass that allows us to pursue business collaborations for clinical development of the technology."

More information is available at www.nexgen.biz under Cell Cycle Synchronous Chemotherapy.


'/>"/>
SOURCE NexGen Biomedical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
2. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
3. Intradigm Receives Notice of Allowance for Key RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
4. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
5. VIASPACE Granted US Patent
6. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
7. VIA Pharmaceuticals Announces Grant of New Patent on Lead Compound VIA-2291
8. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
9. InterMune Announces Issuance of U.S. Patent for ITMN-191
10. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
11. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... YORK , Feb. 11, 2016  Bioethics International, a ... medicines are researched, developed, marketed and made accessible to patients ... BMJ Open had named the publication of the ... 2015. The publication is also featured as one of ... in the last year that are most frequently read. ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... dedicated to delivering cutting-edge information focused on the development and manufacture of ... become a premier sponsor of the 2016 BioProcess International Awards – Recognizing ...
(Date:2/11/2016)...   BioInformant announces the February 2016 release ... Opportunities, Tools, and Technologies – Market Size, Segments, Trends, ... The first and only market ... BioInformant has more than a decade of historical information ... stem cell type. This powerful 175 page global strategic ...
(Date:2/11/2016)... ... 2016 , ... Global Stem Cells Group, has ... The new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine, ... , The new GSCG clinic is headed by four prominent Ecuadorian physicians, including ...
Breaking Biology Technology:
(Date:2/1/2016)... Canada , February 1, 2016 ... technological advancements to drive global touchfree intuitive gesture control ... --> Rising sales of consumer electronics coupled ... gesture control market size through ... consumer electronics coupled with new technological advancements to drive ...
(Date:1/25/2016)... 2016   Unisys Corporation (NYSE: UIS ) today ... (JFK) International Airport, New York City , to ... attempting to enter the United States using ... pilot testing of the system at Dulles last year. ... JFK during January 2016. --> pilot testing of ...
(Date:1/20/2016)... 20, 2016 A market that just keeps ... from the explosion in genomics knowledge. Learn all about ... A range of dynamic trends are pushing market growth ... medicine - pharmacogenomics - pathogen evolution - next generation ... - greater understanding of the role of genetic material ...
Breaking Biology News(10 mins):